Sri Lanka

The primary regulatory authority for health products in Sri Lanka is the National Medicines Regulatory Authority (NMRA), established under the National Medicines Regulatory Authority Act No. 5 of 2015. The NMRA oversees the registration, licensing, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and related health products. Prior to the establishment of the NMRA, regulatory functions were handled under the Cosmetics, Devices and Drugs Act No. 27 of 1980, which has since been largely superseded. All health products intended for sale or distribution in Sri Lanka must be registered with the NMRA before market entry, and applicants must submit a formal dossier for technical evaluation. The approval process involves sequential review stages including administrative screening, technical assessment, and a final registration decision, with timelines varying based on product category and the completeness of the submission.

For pharmaceutical products, the NMRA generally accepts dossiers prepared in accordance with the Common Technical Document (CTD) format, and alignment with ASEAN Common Technical Dossier (ACTD) standards is also recognized given Sri Lanka's participation in regional harmonization efforts. A locally registered agent or authorized representative with a valid NMRA license is required for all foreign manufacturers seeking product registration. Supporting documentation typically includes certificates of pharmaceutical product (CPP) from a recognized regulatory authority, Good Manufacturing Practice (GMP) certificates, product quality data, clinical evidence, and labeling materials compliant with local requirements. For medical devices and in-vitro diagnostics, classification-based requirements apply, with higher-risk devices subject to more rigorous conformity assessment. The NMRA has undertaken ongoing reforms to streamline registration pathways, including the introduction of an online e-submission portal and pilot abridged review routes for products already approved by stringent regulatory authorities (SRAs) such as the US FDA, EMA, TGA, or Health Canada, aimed at reducing duplication of technical review and accelerating access to quality-assured products.

Public sector procurement of health products in Sri Lanka is centrally coordinated through the Ministry of Health (MOH), with the State Pharmaceuticals Corporation (SPC) serving as the principal government agency responsible for the procurement, storage, and distribution of pharmaceuticals and medical supplies to public health facilities nationwide. The SPC operates under the purview of the MOH and conducts national-level tender processes for medicines, medical devices, and diagnostics used across government hospitals, provincial health departments, and primary care institutions. Procurement decisions are governed by the National Procurement Guidelines issued by the National Procurement Commission, and all public tenders are subject to a technical evaluation process that includes assessment of regulatory registration status, quality certification, and supplier track record. The Sri Lanka health system is largely centralized, with the MOH holding primary authority over budgeting and procurement planning, though provincial health directorates may have limited autonomous procurement capacity for certain consumables and operational supplies.

The private sector constitutes a significant channel for health product market access in Sri Lanka, with products distributed through private importers, pharmaceutical wholesalers, retail pharmacies, and private hospital networks operating independently of the SPC supply chain. Private sector procurement is driven by market competition, physician preferences, and patient demand, and requires the same NMRA registration as public sector products. Sri Lanka also benefits from donor-funded health programs, including support from the World Health Organization (WHO), UNICEF, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, particularly for communicable disease programs, diagnostics, and essential medicines. USAID and bilateral development partners have historically supported health systems strengthening initiatives that include supply chain improvements and product access programs. While Sri Lanka does not maintain an explicit mandatory local manufacturing preference policy for general procurement, the government has expressed strategic interest in promoting domestic pharmaceutical manufacturing capacity, and products manufactured locally by NMRA-licensed facilities may benefit from favorable consideration in certain tender evaluations. The ongoing fiscal pressures on the public health system have increased emphasis on cost-effectiveness, generic medicine procurement, and quality assurance as core procurement criteria.